The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and “Nose-to-Brain”
Sino-nasal disease is appropriately treated with topical treatment, where the nasal mucosa acts as a barrier to systemic absorption. Non-invasive nasal delivery of drugs has produced some small molecule products with good bioavailability. With the recent COVID pandemic and the need for nasal mucosal...
Main Author: | Stephen B. Shrewsbury |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/6/1720 |
Similar Items
-
Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols
by: Wafaa Alabsi, et al.
Published: (2022-09-01) -
In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery
by: Aida Maaz, et al.
Published: (2021-07-01) -
Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study
by: Inbar Schlachet, et al.
Published: (2020-09-01) -
Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space
by: Vincent Martin, et al.
Published: (2021-06-01) -
Bi‐directional nasal drug delivery systems: A scoping review of nasal particle deposition patterns and clinical application
by: Yuxing Liu, et al.
Published: (2023-12-01)